Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors-Reference-Cited by-同舟云学术

Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors

Published:2017-06-30 Issue:9 Volume:8 Page:1995-2004
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Wager Travis T.¹^ORCID,Galatsis Paul¹,Chandrasekaran Ramalakshmi Y.¹²,Butler Todd W.¹²,Li Jianke¹²,Zhang Lei¹,Mente Scot¹,Subramanyam Chakrapani¹²,Liu Shenping¹,Doran Angela C.³,Chang Cheng³,Fisher Katherine⁴,Grimwood Sarah⁴,Hedde Joseph R.⁴,Marconi Michael⁴,Schildknegt Klaas⁵

Affiliation:

1. Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 1 Portland, Cambridge, Massachusetts 02139, United States

2. Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, 558 Eastern Point Rd, Groton, Connecticut 06340, United States

3. Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, 558 Eastern Point Rd, Groton, Connecticut 06340, United States

4. Internal Medicine Research Unit, Pfizer Worldwide Research and Development, 1 Portland, Cambridge, Massachusetts 02139, United States

5. Chemical Research and Development, Pharmaceutical Sciences, Pfizer Worldwide Research and Development, 558 Eastern Point Rd, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.7b00155

Reference12 articles.

1. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

2. Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand

3. In vivo site-directed radiotracers: a mini-review

4. Ligand–Protein Interactions of Selective Casein Kinase 1δ Inhibitors

5. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation;Neurobiology of Disease;2024-06

2. Casein kinase (CK) inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

3. Challenges and Perspectives in Target Identification and Mechanism Illustration for Chinese Medicine;Chinese Journal of Integrative Medicine;2023-02-21

4. Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders;Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders;2023

5. POSITRON EMISSION TOMOGRAPHY NEUROIMAGING IN DRUG DISCOVERY AND DEVELOPMENT;2022 Medicinal Chemistry Reviews;2022-12-21